According to Galmed Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of 0.1514.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 0.1173 | -87.51% |
2022-12-31 | 0.9388 | -37.29% |
2021-12-31 | 1.50 | -0.28% |
2020-12-31 | 1.50 | -14.18% |
2019-12-31 | 1.75 | 7.09% |
2018-12-31 | 1.63 | -79.45% |
2017-12-31 | 7.95 | 106.43% |
2016-12-31 | 3.85 | -1.8% |
2015-12-31 | 3.92 | 91.27% |
2014-12-31 | 2.05 | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Evoke Pharma
EVOK | -1.51 | -1,094.40% | ๐บ๐ธ USA |
Endo International
ENDPQ | 0.0000 | -100.01% | ๐ฎ๐ช Ireland |
Catalent CTLT | 2.75 | 1,714.25% | ๐บ๐ธ USA |